Cartesian Therapeutics (RNAC) Tops Q2 EPS by 50c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts RNAC Hot Sheet
Join SI Premium – FREE
Cartesian Therapeutics (NASDAQ: RNAC) reported Q2 EPS of $0.50. Revenue for the quarter came in at $300 thousand.
For earnings history and earnings-related data on Cartesian Therapeutics (RNAC) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Acadia Pharma (ACAD) Tops Q3 EPS by 11c, Beats on Revenue; Offers FY26 Revenue Guidance
- Aeva Technologies, Inc. (AEVA) Tops Q3 EPS by 4c
- Qualcomm (QCOM) Reports In-Line Q4 EPS, Beats on Revenue; Offers Q1 Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
